newsfilter
← Latest News
GlobeNewswire·

Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021

-SIVEXTRO® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as of 12/31/21